Vicore’s C21 reduces long-term lung injury after COVID-19 in the ATTRACT Phase 2 extension study
· The results showed nearly 50% reduction in lung injury in the C21 group compared with theplacebo group · These positive findings together with previous clinical results[1 ]suggest that C21 could accelerate recovery · C21 is currently being evaluated in a phase 3 trial in COVID-19 patientsGothenburg, November 2, 2021 - Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders today announces results that treatment with the company’s AT2R agonist C21 reduces long-term lung injury in hospitalized COVID-